JRF106

N/A

Report date: 2025/08/27 15:13:34
NME

Base Information

Drug NameJRF106
Drug Alias NameJRF-106JRF106
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSolute carrier family 12 member 2 antagonistsSodium-(potassium)-chloride cotransporter 2 inhibitors
TargetsSolute carrier family 12 member 2Sodium-(potassium)-chloride cotransporter 2
Therapy Area/IndicationsPulmonary EdemaAsthmaSmall Cell Lung Carcinoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesChengdu Jinrui Foundation Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChengdu Jinrui Foundation Biotechnology Co LtdJoincare Pharmaceutical Group Industry Co Ltd
Inactive CompaniesN/A
Active IndicationsPulmonary EdemaAsthma
Inactive IndicationsSmall Cell Lung CarcinomaLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A